Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Eton Pharmaceuticals (ETON) EBITDA Margin (2019 - 2025)

Historic EBITDA Margin for Eton Pharmaceuticals (ETON) over the last 7 years, with Q3 2025 value amounting to 6.07%.

  • Eton Pharmaceuticals' EBITDA Margin fell 110000.0% to 6.07% in Q3 2025 from the same period last year, while for Sep 2025 it was 4.89%, marking a year-over-year increase of 42400.0%. This contributed to the annual value of 6.66% for FY2024, which is 28900.0% down from last year.
  • As of Q3 2025, Eton Pharmaceuticals' EBITDA Margin stood at 6.07%, which was down 110000.0% from 7.79% recorded in Q2 2025.
  • Over the past 5 years, Eton Pharmaceuticals' EBITDA Margin peaked at 45.08% during Q1 2021, and registered a low of 754.45% during Q3 2021.
  • Over the past 5 years, Eton Pharmaceuticals' median EBITDA Margin value was 7.8% (recorded in 2023), while the average stood at 63.36%.
  • Over the last 5 years, Eton Pharmaceuticals' EBITDA Margin had its largest YoY gain of 226141900bps in 2021, and its largest YoY loss of 2000000000bps in 2021.
  • Quarter analysis of 5 years shows Eton Pharmaceuticals' EBITDA Margin stood at 21.57% in 2021, then tumbled by -42bps to 12.5% in 2022, then tumbled by -154bps to 6.69% in 2023, then surged by 181bps to 5.4% in 2024, then plummeted by -212bps to 6.07% in 2025.
  • Its last three reported values are 6.07% in Q3 2025, 7.79% for Q2 2025, and 26.32% during Q1 2025.